Bristol-Myers Squibb Company (NYSE:BMY) announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo ® (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.Original Article
Bristol-Myers Squibb’s Opdivo® (nivolumab) now the first and only FDA-approved PD-1 inhibitor to offer every four-week dosing
